+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Sjogren's Syndrome (SS) - Market Insights, Epidemiology and Market Forecast to 2028

  • ID: 4827850
  • Drug Pipelines
  • 192 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2019
1 of 3

FEATURED COMPANIES

  • ADVANZ Pharma
  • Daiichi Sankyo
  • Incyte Corporation
  • Novartis
  • Resolve Therapeutics
  • TearSolutions
  • MORE
‘Sjogren’s Syndrome (SS)-Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Sjogren’s Syndrome in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Sjogren’s Syndrome from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Sjogren’s Syndrome - Disease Understanding and Treatment Algorithm
The Sjogren’s Syndrome market report gives a thorough understanding of SS by including details, such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Sjogren’s Syndrome in the US, Europe, and Japan.

Sjogren’s Syndrome Epidemiology
The Sjogren’s Syndrome epidemiology division provide insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by Diagnosed Prevalent cases, Gender-specific cases, Type-specific cases [Primary Sjogren’s Syndrome (pSS), Secondary Sjogren’s Syndrome (sSS)] and Severity-specific cases [Mild and Moderate to Severe] in the 7MM.

According to the author, the total diagnosed prevalent cases of Sjogren’s Syndrome were 3,270,396 in 2017 in 7MM.

Sjogren’s Syndrome Drug Chapters
This segment of the Sjogren’s Syndrome report encloses the detailed analysis of marketed drugs and late stage (Phase-II and III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Sjogren’s Syndrome Market Outlook
The Sjogren’s Syndrome market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The current market of SS is majorly driven by the growing prevalence and awareness, development of better classification criteria, increased research and development and identification of potential biomarkers. Sjogren’s syndrome is a multisystem disorder that is heterogeneous in its presentation, course, and outcome. There is still no single clinical, laboratory, pathological, or radiological feature that could serve as a ‘gold standard’ for the diagnosis and/or classification of this syndrome. Labial salivary gland biopsy with a subsequent histopathological evaluation is currently in use. Consequently, the development of criteria for use in both clinical care, as well as research studies, has been an important challenge in Sjogren’s syndrome. Hitherto, the therapeutic market size of Sjögren’s syndrome is mainly accounted by symptomatic treatment including local therapies (pilocarpine, cevimeline, topical fluoride, topical cyclosporine, autologous serum eye drops, and others), systemic therapies (corticosteroids, hydroxychloroquine) and immunosuppressants (Methotrexate (MTX), Cyclosporine A, Azathioprine, Leflunomide, and Mycophenolic acid) which are commonly used interventions. Moreover, biological therapy with Rituximab is in extensive use for the US market.

As per the author's estimates, the market size of SS was found to be USD 2,427.47 million in 2017. This market is further expected to grow during the forecasted period of 2019–2028 owing to the launch of upcoming therapies. Detailed chapters of the promising upcoming therapies, including RSLV-132(Resolve Therapeutics), VAY 736 (Novartis), CFZ533 (Novartis), Belimumab (GlaxoSmithKline), R05459072 (Roche), LOU-064 (Novartis), Abatacept (Bristol Myers Squibb), Lacricep (Tearsolutions), Parsaclisib (Incyte Corporation), Filgotinib (Gilead Sciences), GS-9876 (Gilead Sciences), and VIB7734 (VIELABIO), etc. are also provided in the report.

Sjogren’s Syndrome Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Sjogren’s Syndrome Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Sjogren’s Syndrome Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Sjogren’s Syndrome Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving the Sjogren’s Syndrome market.
  • Organize sales and marketing efforts by identifying the best opportunities for Sjogren’s Syndrome market.
  • To understand the future market competition in the Sjogren’s Syndrome market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • ADVANZ Pharma
  • Daiichi Sankyo
  • Incyte Corporation
  • Novartis
  • Resolve Therapeutics
  • TearSolutions
  • MORE
1. Key Insights

2. Sjögren’s Syndrome (SS): Market Overview at a Glance
2.1. Market Share (%) Distribution of SS in 2017
2.2. Market Share (%) Distribution of SS in 2028

3. Disease Overview: Sjögren’s syndrome
3.1. Introduction
3.2. Classification of Sjogren’s Syndrome
3.3. Signs and Symptoms
3.4. Etiology
3.5. Pathogenesis
3.6. Biomarkers in Sjogren’s Syndrome
3.7. Diagnosis of Sjogren’s Syndrome
3.7.1. Differential Diagnosis

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Total Diagnosed Prevalent Patient Population of Sjögren’s Syndrome
4.3. Country Wise-Epidemiology of Sjögren’s syndrome
4.4. United States
4.4.1. Assumptions and Rationale
4.4.2. Diagnosed Prevalent Cases of Sjögren’s syndrome in the United States
4.4.3. Gender-Specific Cases of Sjögren’s syndrome in the US
4.4.4. Type-Specific Cases of Sjögren’s syndrome in the US
4.4.5. Severity-Specific Cases of Sjögren’s syndrome in the US
4.5. Germany
4.5.1. Assumptions and Rationale
4.5.2. Diagnosed Prevalent Cases of Sjögren’s syndrome in Germany
4.5.3. Gender-Specific Cases of Sjögren’s syndrome in Germany
4.5.4. Type-Specific Cases of Sjögren’s syndrome in Germany
4.5.5. Severity-Specific Cases of Sjögren’s syndrome in Germany
4.6. France
4.6.1. Assumptions and Rationale
4.6.2. Diagnosed Prevalent Cases of Sjögren’s syndrome in France
4.6.3. Gender-Specific Cases of Sjögren’s syndrome in France
4.6.4. Type-Specific Cases of Sjögren’s syndrome in France
4.6.5. Severity-Specific Cases of Sjögren’s syndrome in France
4.7. Italy
4.7.1. Assumptions and Rationale
4.7.2. Diagnosed Prevalent Cases of Sjögren’s syndrome in Italy
4.7.3. Gender-Specific Cases of Sjögren’s syndrome in Italy
4.7.4. Type-Specific Cases of Sjögren’s syndrome in Italy
4.7.5. Severity-Specific Cases of Sjögren’s syndrome in Italy
4.8. Spain
4.8.1. Assumptions and Rationale
4.8.2. Diagnosed Prevalent Cases of Sjögren’s syndrome in Spain
4.8.3. Gender-Specific Cases of Sjögren’s syndrome in Spain
4.8.4. Type-Specific Cases of Sjögren’s syndrome in Spain
4.8.5. Severity-Specific Cases of Sjögren’s syndrome in Spain
4.9. United Kingdom
4.9.1. Assumptions and Rationale
4.9.2. Diagnosed Prevalent Cases of Sjögren’s syndrome in the United Kingdom
4.9.3. Gender-Specific Cases of Sjögren’s syndrome in the United Kingdom
4.9.4. Type-Specific Cases of Sjögren’s syndrome in the UK
4.9.5. Severity-Specific Cases of Sjögren’s syndrome in the United Kingdom
4.10. Japan
4.10.1. Assumptions and Rationale
4.10.2. Diagnosed Prevalent Cases of Sjögren’s syndrome in Japan
4.10.3. Gender-Specific Cases of Sjögren’s syndrome in Japan
4.10.4. Type-Specific Cases of Sjögren’s syndrome in Japan
4.10.5. Severity-Specific Cases of Sjögren’s syndrome in Japan

5. Current Treatment Practices
5.1. United States Treatment Guidelines for Sjögren’s Disease
5.2. Evidence-based medicine clinical practice guidelines (US, EU, JP)

6. Unmet Needs

7. Marketed Drugs
7.1. Salagen: ADVANZ Pharma
7.1.1. Drug Description
7.1.2. Regulatory Milestones
7.1.3. Safety and Efficacy
7.1.4. Product Profile
7.2. Evoxac: Daiichi Sankyo
7.2.1. Drug Description
7.2.2. Regulatory Milestones
7.2.3. Clinical Development
7.2.4. Safety and Efficacy
7.2.5. Product Profile

8. Emerging Therapies
8.1. Key cross competition- Emerging Therapies
8.2. RSLV-132: Resolve Therapeutics
8.2.1. Drug Description
8.2.2. Other Developmental Activities
8.2.3. Clinical Development
8.2.4. Safety and Efficacy
8.2.5. Product Profile
8.3. VAY736: Novartis/MorphoSys
8.3.1. Drug Description
8.3.2. Other Developmental Activities
8.3.3. Clinical Development
8.3.4. Safety and Efficacy
8.3.5. Product Profile
8.4. CFZ533: Novartis
8.4.1. Drug Description
8.4.2. Clinical Development
8.4.3. Product Profile
8.5. Belimumab: GlaxoSmithKline
8.5.1. Drug Description
8.5.2. Other Developmental Activities
8.5.3. Clinical Development
8.5.4. Safety and Efficacy
8.5.5. Product Profile
8.6. RO5459072: Roche
8.6.1. Product Description
8.6.2. Clinical Development
8.6.3. Safety and Efficacy
8.6.4. Product Profile
8.7. LOU-064: Novartis
8.7.1. Drug Description
8.7.2. Clinical Development
8.7.3. Product Profile
8.8. Abatacept: Bristol Myers Squibb
8.8.1. Product Description
8.8.2. Other Development Activities
8.8.3. Clinical Development
8.8.4. Safety and Efficacy
8.8.5. Product Profile
8.9. Lacripep: TearSolutions
8.9.1. Product Description
8.9.2. Other Development Activities
8.9.3. Clinical Development
8.9.4. Product Profile
8.10. Parsaclisib: Incyte Corporation
8.10.1. Drug Description
8.10.2. Other Development Activities
8.10.3. Clinical Development
8.10.4. Product Profile
8.11. Filgotinib: Galapagos NV /Gilead Sciences
8.11.1. Drug Description
8.11.2. Other Developmental Activities
8.11.3. Clinical Development
8.11.4. Product Profile
8.12. GS-9876: Gilead Sciences
8.12.1. Drug Description
8.12.2. Other Developmental Activities
8.12.3. Clinical Development
8.12.4. Product Profile
8.13. VIB7734: VIELABIO
8.13.1. Drug Description
8.13.2. Other Developmental Activities
8.13.3. Clinical Development
8.13.4. Product Profile

9. Sjögren’s Syndrome: 7 Major Market Analysis
9.1. Key Findings
9.2. Market Size of Sjögren’s Syndrome in 7MM

10. Market Outlook by Country

11. The United States: Market Outlook
11.1. United States Market Size
11.1.1. Total Market Size of Sjögren’s syndrome
11.1.2. Market Size of Primary Sjögren’s syndrome by Therapies
11.1.3. Market Size of Secondary Sjögren’s syndrome by Therapies

12. EU-5 Countries: Market Outlook
12.1. Germany
12.1.1. Total Market Size of Sjögren’s syndrome
12.1.2. Market Size of Primary Sjögren’s syndrome by Therapies
12.1.3. Market Size of Secondary Sjögren’s syndrome by Therapies
12.2. France
12.2.1. Total Market Size of Sjögren’s syndrome
12.2.2. Market Size of Primary Sjögren’s syndrome by Therapies
12.2.3. Market Size of Secondary Sjögren’s syndrome by Therapies
12.3. Italy
12.3.1. Total Market Size of Sjögren’s syndrome
12.3.2. Market Size of Primary Sjögren’s syndrome by Therapies
12.3.3. Market Size of Secondary Sjögren’s syndrome by Therapies
12.4. Spain
12.4.1. Total Market Size of Sjögren’s syndrome
12.4.2. Market Size of Primary Sjögren’s syndrome by Therapies
12.4.3. Market Size of Secondary Sjögren’s syndrome by Therapies
12.5. United Kingdom
12.5.1. Total Market Size of Sjögren’s syndrome
12.5.2. Market Size of Primary Sjögren’s syndrome by Therapies
12.5.3. Market Size of Secondary Sjögren’s syndrome by Therapies
12.6. Japan: Market Outlook
12.6.1. Total Market Size of Sjögren’s syndrome
12.6.2. Market Size of Primary Sjögren’s syndrome by Therapies
12.6.3. Market Size of Secondary Sjögren’s syndrome by Therapies

13. Market Drivers

14. Market Barriers

15. Appendix

16. Report Methodology

17. Capabilities

18. Disclaimer

19. About the Author

20. Disclaimer

List of Tables
Table 1: American-European Consensus Group Criteria- Revised international classification criteria for Sjögren’s syndrome
Table 2: Revised rules for classification - American-European Consensus Group Criteria
Table 3: ACR/EULAR criteria
Table 4: Selected Non-HLA genes implicated in SS
Table 5: Biomarkers in Primary Sjogren’s syndrome
Table 6: Diagnostic tests to evaluate sicca symptoms in patients with Sjogren’s Syndrome
Table 7: Evaluation of Dry Eye
Table 8: Comparison of the Revised AECG Classification criteria and the ACR Classification criteria for Sjögren's syndrome
Table 9: Diagnosed Prevalent Patient Population of Sjögren’s syndrome in 7MM (2017–2028)
Table 10: Diagnosed Prevalent Cases of Sjögren’s syndrome in the United States (2017–2028)
Table 11: Gender-specific cases of Sjögren’s syndrome in the United States (2017–2028)
Table 12: Type-specific Cases of Sjögren’s syndrome in the United States (2017–2028)
Table 13: Severity-specific Cases of Sjögren’s syndrome in the United States (2017–2028)
Table 14: Diagnosed Prevalent Cases of Sjögren’s syndrome in Germany (2017–2028)
Table 15: Gender-specific cases of Sjögren’s syndrome in Germany (2017–2028)
Table 16: Type-specific Cases of Sjögren’s syndrome in Germany (2017–2028)
Table 17: Severity-specific Cases of Sjögren’s syndrome in Germany (2017–2028)
Table 18: Diagnosed Prevalent Cases of Sjögren’s syndrome in France (2017–2028)
Table 19: Gender-specific cases of Sjögren’s syndrome in France (2017–2028)
Table 20: Type-specific Cases of Sjögren’s syndrome in France (2017–2028)
Table 21: Severity-specific Cases of Sjögren’s syndrome in France (2017–2028)
Table 22: Diagnosed Prevalent Cases of Sjögren’s syndrome in Italy (2017–2028)
Table 23: Gender-specific cases of Sjögren’s syndrome in Italy (2017–2028)
Table 24: Type-specific Cases of Sjögren’s syndrome in Italy (2017–2028)
Table 25: Severity-specific Cases of Sjögren’s syndrome in Italy (2017–2028)
Table 26: Diagnosed Prevalent Cases of Sjögren’s syndrome in Spain (2017–2028)
Table 27: Gender-specific cases of Sjögren’s syndrome in Spain (2017–2028)
Table 28: Type-specific Cases of Sjögren’s syndrome in Spain (2017–2028)
Table 29: Severity-specific Cases of Sjögren’s syndrome in Spain (2017–2028)
Table 30: Diagnosed Prevalent Cases of Sjögren’s syndrome in the United Kingdom (2017–2028)
Table 31: Gender-specific cases of Sjögren’s syndrome in the United Kingdom (2017–2028)
Table 32: Type-specific Cases of Sjögren’s syndrome in the UK (2017–2028)
Table 33: Severity-specific Cases of Sjögren’s syndrome in the United Kingdom (2017–2028)
Table 34: Diagnosed Prevalent Cases of Sjögren’s syndrome in Japan (2017–2028)
Table 35: Gender-specific cases of Sjögren’s syndrome in Japan (2017–2028)
Table 36: Type-specific Cases of Sjögren’s syndrome in Japan (2017–2028)
Table 37: Severity-specific Cases of Sjögren’s syndrome in Japan (2017–2028)
Table 38: Oral management guidelines for caries prophylaxis
Table 39: Guidelines for DMARDS use for musculoskeletal pain in SS
Table 40: Guidelines for the treatment of fatigue in Sjogren’s disease
Table 41: Guidelines for the use of biological medications in Sjogren’s disease
Table 42: Currently available evidence-based medicine clinical practice guidelines on diagnosis and management of SS
Table 43: Evoxac, Clinical Trial Description, 2018
Table 44: Emerging Drugs Analysis
Table 45: Emerging Drugs Analysis
Table 46: RSLV-132, Clinical Trial Description, 2019
Table 47: VAY736, Clinical Trial Description, 2019
Table 48: CFZ533, Clinical Trial Description, 2018
Table 49: Belimumab, Clinical Trial Description, 2019
Table 50: RO5459072, Clinical Trial Description, 2019
Table 51: LOU-064, Clinical Trial Description, 2019
Table 52: Abatacept, Clinical Trial Description, 2019
Table 53: Lacripep, Clinical Trial Description, 2019
Table 54: Parsaclisib, Clinical Trial Description, 2019
Table 55: Filgotinib, Clinical Trial Description, 2019
Table 56: GS-9876, Clinical Trial Description, 2019
Table 57: VIB7734, Clinical Trial Description, 2019
Table 58: 7 Major Market Size of Sjögren’s syndrome in USD Million (2017–2028)
Table 59: United States Market Size of Sjögren’s syndrome in USD Million (2017–2028)
Table 60: Market Size of Primary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Table 61: Market Size of Secondary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Table 62: Germany Market Size of Sjögren’s syndrome in USD Million (2017–2028)
Table 63: Market Size of Primary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Table 64: Market Size of Secondary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Table 65: France Market Size of Sjögren’s syndrome in USD Million (2017–2028)
Table 66: Market Size of Primary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Table 67: Market Size of Secondary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Table 68: Italy, Market Size of Sjögren’s syndrome in USD Million (2017–2028)
Table 69: Market Size of Primary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Table 70: Market Size of Secondary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Table 71: Spain, Market Size of Sjögren’s syndrome in USD Million (2017–2028)
Table 72: Market Size of Primary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Table 73: Market Size of Secondary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Table 74: UK Market Size of Sjögren’s syndrome in USD Million (2017–2028)
Table 75: Market Size of Primary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Table 76: Market Size of Secondary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Table 77: Japan, Market Size of Sjögren’s syndrome in USD Million (2017–2028)
Table 78: Market Size of Primary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Table 79:Market Size of Secondary Sjögren’s syndrome by Therapies in USD Million (2017–2028)

List of Figures
Figure 1: Clinical spectrum Sjogren’s syndrome
Figure 2: The Pathogenesis of autoimmune epitelitis as a potential explanation for Sjogren’s Syndrome
Figure 3: Interplay of immune and non-immune factors in the pathophysiology of Sjogren’s Syndrome
Figure 4: Diagnosed Prevalent Patient Population of Sjögren’s syndrome in 7MM (2017–2028)
Figure 5: Diagnosed Prevalent Cases of Sjögren’s syndrome in the United States (2017–2028)
Figure 6: Gender-specific Diagnosed Prevalent Cases of Sjögren’s syndrome in the US (2017–2028)
Figure 7: Type-specific Diagnosed Prevalent Cases of Sjögren’s syndrome in the US (2017–2028)
Figure 8: Severity-specific Cases of Sjögren’s syndrome in the US (2017–2028)
Figure 9: Diagnosed Prevalent Cases of Sjögren’s syndrome in Germany (2017–2028)
Figure 10: Gender-specific of Sjögren’s syndrome in Germany (2017–2028)
Figure 11: Type-specific Diagnosed Prevalent Cases of Sjögren’s syndrome in Germany (2017–2028)
Figure 12: Severity-specific Cases of Sjögren’s syndrome in Germany (2017–2028)
Figure 13: Diagnosed Prevalent Cases of Sjögren’s syndrome in France (2017–2028)
Figure 14: Gender-specific Cases of Sjögren’s syndrome in France (2017–2028)
Figure 15: Type-specific Diagnosed Prevalent Cases of Sjögren’s syndrome in France (2017–2028)
Figure 16: Severity-specific Cases of Sjögren’s syndrome in France (2017–2028)
Figure 17: Diagnosed Prevalent Cases of Sjögren’s syndrome in Italy (2017–2028)
Figure 18: Gender-specific Cases of Sjögren’s syndrome in Italy (2017–2028)
Figure 19: Type-specific Diagnosed Prevalent Cases of Sjögren’s syndrome in Italy (2017–2028)
Figure 20: Severity-specific Cases of Sjögren’s syndrome in Italy (2017–2028)
Figure 21: Diagnosed Prevalent Cases of Sjögren’s syndrome in Spain (2017–2028)
Figure 22: Gender-specific Cases of Sjögren’s syndrome in Spain (2017–2028)
Figure 23: Type-specific Diagnosed Prevalent Cases of Sjögren’s syndrome in Spain (2017–2028)
Figure 24: Severity-specific Cases of Sjögren’s syndrome in Spain (2017–2028)
Figure 25: Diagnosed Prevalent Cases of Sjögren’s syndrome in the United Kingdom (2017–2028)
Figure 26: Gender-specific Cases of Sjögren’s syndrome in the United Kingdom (2017–2028)
Figure 27: Type-specific Diagnosed Prevalent Cases of Sjögren’s syndrome in the UK (2017–2028)
Figure 28: Severity-specific Cases of Sjögren’s syndrome in the UK (2017–2028)
Figure 29: Diagnosed Prevalent Cases of Sjögren’s syndrome in Japan (2017–2028)
Figure 30: Gender-specific Cases of Sjögren’s syndrome in Japan (2017–2028)
Figure 31: Type-specific Diagnosed Prevalent Cases of Sjögren’s syndrome in Japan (2017–2028)
Figure 32: Severity -specific Cases of Sjögren’s syndrome in Japan (2017–2028)
Figure 33: Unmet Needs of Sjogren’s syndrome
Figure 34: 7 Major Market Size of Sjögren’s syndrome in USD Million (2017–2028)
Figure 35: Market Size of Sjögren’s syndrome in the United States, USD Millions (2017–2028)
Figure 36: Market Size of Primary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Figure 37: Market Size of Secondary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Figure 38: Market Size of Sjögren’s syndrome in Germany, USD Millions (2017–2028)
Figure 39: Market Size of Primary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Figure 40: Market Size of Secondary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Figure 41: Market Size of Sjögren’s syndrome in France, USD Millions (2017–2028)
Figure 42: Market Size of Primary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Figure 43: Market Size of Secondary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Figure 44: Market Size of Sjögren’s syndrome in Italy, USD Millions (2017–2028)
Figure 45: Market Size of Primary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Figure 46: Market Size of Secondary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Figure 47: Market Size of Sjögren’s syndrome in Spain, USD Millions (2017–2028)
Figure 48: Market Size of Primary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Figure 49: Market Size of Secondary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Figure 50: Market Size of Sjögren’s syndrome in the UK, USD Millions (2017–2028)
Figure 51: Market Size of Primary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Figure 52: Market Size of Secondary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Figure 53: Market Size of Sjögren’s syndrome in Japan, USD Millions (2017–2028)
Figure 54: Market Size of Primary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Figure 55: Market Size of Secondary Sjögren’s syndrome by Therapies in USD Million (2017–2028)
Figure 56: Market Drivers
Figure 57: Market Barriers
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • ADVANZ Pharma
  • Daiichi Sankyo
  • Resolve Therapeutics
  • Novartis MorphoSys
  • Novartis
  • GlaxoSmithKline
  • Roche
  • Novartis
  • Bristol Myers Squibb
  • TearSolutions
  • Incyte Corporation
  • Galapagos NV Gilead Sciences
  • VIELABIO
Note: Product cover images may vary from those shown
Adroll
adroll